mechanism of glp 1 receptor agonist Frontiers GLP1 Receptor Agonists—Effects beyond Obesity
Description
Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis
Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Additionally, in a post-hoc analysis of the SURPASS-4 trials, tirzepatide showed a slower rate of eGFR decline and lower urinary albumin creatinine values as compared to patients who were treated with glargine insulin [75, 76]
If we had a treatment for obesity, they wouldn't have had that' (Hickey)
